- Policy
- Off-label Mabthera use on NMO patient rejected
- by Lee, Hye-Kyung Mar 9, 2020 07:59am
- Non-reimbursed use of Mabthera injection (rituximab) on a female patient with neuromyelitis optica (NMO), who is planning on a pregnancy, has been denied. Korea’s Health Insurance Review and Assessment Service (HIRA) preliminarily reviews off-label non-reimbursed use of drugs to prevent using drugs lacking medical evidence or having saf
- Policy
- ₩11 trillion is organized in supplementary budget
- by Lee, Jeong-Hwan Mar 6, 2020 06:06am
- The government will finalize the revised supplementary budget for COVID-19 at &8361;11.7 trillion and submit it to the National Assembly. The budget details include reinforcing infectious disease prevention system, restoration of damages to small business owners, support for public welfare and employment, and support for stagnant local e
- Policy
- COVID-19 Special Committee announced a“Pincette Meeting”
- by Lee, Jeong-Hwan Mar 5, 2020 06:34am
- The National Assembly's COVID-19 Countermeasures Special Committee is the first to resolve the issue of 'Daegu hospital bed & medical facilities shortage' and 'mask shortages' and will hold a 'Pincette Meeting' for about 4 hours. The committee decided to receive a report on issues related to the lack of mask supply to the MFDS, the Ministr
- Policy
- Remdesivir, clinical trial of 195 patients with COVID-19
- by Lee, Tak-Sun Mar 5, 2020 06:33am
- Gilead Science's 'Remdesivir', which is attracting attention as a treatment for COVID-19, is conducting clinical trials on a total of 195 patients in Korea. There are three medical institutions with clinical trials: Kyungpook National University Hospital, National Medical Center, and Seoul Medical Center. The Ministry of Food and Drug S
- Policy
- Finalized gradual drug pricing in effect from July
- by Kim, Jung-Ju Mar 4, 2020 06:27am
- The government finalized the so-called ‘gradual drug pricing system revision’ that differentiates reimbursed generic pricing based on individual bioequivalence test. The approval qualification and pricing linkage, such as conducting individual bioequivalence test and using registered substance with DMF, would come in effect from July 1. Wh
- Policy
- The supply cost of NIP quadrivalent flu vaccine is absurd
- by Lee, Tak-Sun Mar 3, 2020 06:09am
- Manufacturers are opposing the government's pricing policy ahead of the Quadrivalent flu Vaccine (NIP) program. Damages will be inevitable by setting a budget without considering production costs more expensive than trivalent vaccines. In particular, pharmaceutical companies are complaining that they have to take losses because medical
- Policy
- MOHW to speed up anticancer therapy reimbursement review
- by Lee, Jeong-Hwan Mar 3, 2020 06:09am
- The Korean health authority is to expedite the reimbursement review procedure for the latest anticancer therapies including Imfinzi, Bavencio, and Tecentriq. The authority is also reviewing data submitted by Opdivo and Keytruda for their additional indications. On Feb. 28, Ministry of Health and Welfare (MOHW) Pharmaceutical Benefits
- Policy
- The government invests ₩16 trillion for COVID-19
- by Lee, Jeong-Hwan Mar 3, 2020 06:09am
- The government announced on the 28th that it would invest about &8361;16 trillion to finance, tax and banking to solve the problems caused by the spread of COVID-19. From March to June, the check and credit card income deduction rate will be doubled to the previous level, and individual consumption tax will be cut by 70%. VAT payments
- Policy
- Remdesivir, Phase III clinical trials are imminent in Korea
- by Lee, Tak-Sun Mar 2, 2020 06:22am
- Gilead has applied for Remdesivir’s IND for COVID-19 patients at the MFDS. In Asian countries, including Korea (excluding China), the study targets 1000 patients. There is no country-specific number of subjects, but it is known to be recruited on a first come, first served basis. The MFDS announced that Gilead submitted a Phase III cli
- Policy
- Single Hib vaccine Vaxem Hib exits Korean market
- by Lee, Tak-Sun Mar 2, 2020 06:21am
- Apparently, there are now only two single Haemophilus influenzae type b (Hib) vaccines left in the market that prevents cerebromeningitis in children by blocking Hib bacteria. Experts analyze, although a part of National Immunization Program, single Hib vaccine has lost its competitiveness in Korean market against other combination vac
